Skip to main content
SpringerLink
Log in

Beeinflussung der glomerulären Filtrationsrate durch SGLT2-Inhibitoren

Impact of SGLT2 inhibitors on glomerular filtration rate

  • Wie funktioniert es?
  • Published:
Der Nephrologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Kohan DE, Fioretto P, Johnsson K et al (2016) The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol 29:391–400

    Article  CAS  Google Scholar 

  2. Mosenzon O, Wiviott SD, Cahn A et al (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 7:606–617

    Article  CAS  Google Scholar 

  3. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657

    Article  CAS  Google Scholar 

  4. Perkovic V, De Zeeuw D, Mahaffey KW et al (2018) Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol 6:691–704

    Article  CAS  Google Scholar 

  5. Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306

    Article  CAS  Google Scholar 

  6. Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of Kidney Disease in type 2 diabetes. N Engl J Med 375:323–334

    Article  CAS  Google Scholar 

  7. Wiviott SD, Raz I, Bonaca MP et al (2018) The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. American Heart Journal 200:83–89

    Article  CAS  Google Scholar 

  8. Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357

    Article  CAS  Google Scholar 

  9. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373:2117–2128

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Physiologie, Universität Regensburg, Universitätsstraße 31, 93053, Regensburg, Deutschland

    P. Tauber

Authors
  1. P. Tauber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Tauber.

Ethics declarations

Interessenkonflikt

P. Tauber gibt an, dass kein Interessenkonflikt besteht.

Additional information

Redaktion

F. Schweda, Regensburg

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tauber, P. Beeinflussung der glomerulären Filtrationsrate durch SGLT2-Inhibitoren. Nephrologe 15, 114–118 (2020). https://doi.org/10.1007/s11560-019-00394-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-019-00394-6

Search

Navigation